This study evaluated the efficacy and safety of vibegron, a beta-3 adrenergic receptor (3-AR) agonist, in the treatment of pain associated with IBS due to IBS-D or mixed episodes of diarrhea and constipation (IBS-M). The gene discussed is ADRB3; the disease is irritable bowel syndrome.